Bribery Scandal Dents Big Pharma Sales in China, GSK Hardest Hit

A crackdown on corruption in China’s pharmaceutical sector, reports Reuters, has hurt sales at international and local firms, with many doctors at Chinese hospitals refusing to see drug representatives for fear of being caught up in the widening scandal. Britain’s GlaxoSmithKline Plc, the group at the center of the furor, has suffered the most. Industry insiders expect its China drug sales growth to slow sharply or even reverse in the third quarter after a 14 percent year-on-year rise in the last three months.